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Neuropathic pain remains poorly treated for large numbers of patients, and little progress has been made in developing novel
classes of analgesics. To redress this issue, ziconotide (Prialt™) was developed and approved as a ﬁrst-in-class synthetic version of
ω-conotoxin MVIIA, a peptide blocker of Cav2.2 channels. Unfortunately, the impracticalities of intrathecal delivery, low
therapeutic index and severe neurological side effects associated with ziconotide have restricted its use to exceptional
circumstances. Ziconotide exhibits no state or use-dependent block of Cav2.2 channels; activation state-dependent blockers were
hypothesized to circumvent the side effects of state-independent blockers by selectively targeting high-frequency ﬁring of
nociceptive neurones in chronic pain states, thus alleviating aberrant pain but not affecting normal sensory transduction.
Unfortunately, numerous drugs, including state-dependent calcium channel blockers, have displayed efﬁcacy in preclinical
models but have subsequently been disappointing in clinical trials. In recent years, it has become more widely acknowledged that
trans-aetiological sensory proﬁles exist amongst chronic pain patients and may indicate similar underlying mechanisms and drug
sensitivities. Heterogeneity amongst patients, a reliance on stimulus-evoked endpoints in preclinical studies and a failure to utilize
translatable endpoints, all are likely to have contributed to negative clinical trial results. We provide an overview of how
electrophysiological and operant-based assays provide insight into sensory and affective aspects of pain in animal models and
how these may relate to chronic pain patients in order to improve the bench-to-bedside translation of calcium channel
modulators.
Abbreviations
CPM, conditioned pain modulation; CPP, conditioned place preference; CRMP2, collapsin response mediator protein 2;
DRG, dorsal root ganglion; NNT, number needed to treat; NS, nociceptive speciﬁc; SNL, spinal nerve ligation; VGCC,
voltage-gated calcium channel; VPL, ventral posterolateral; WDR, wide dynamic range
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Introduction
Neuropathic syndromes are often characterized by a complex
combination of positive and negative sensory phenomena
including allodynia (perceiving non-noxious stimuli as
pain), hyperalgesia (increased pain to normally painful
stimuli) and also paroxysmal or persistent paraesthesias
(abnormal sensations, e.g. numbness and tingling) and
dysaesthesias (abnormal and unpleasant sensations, e.g.
shocking and paradoxical burning). These symptoms are
often confounded by co-morbidities such as depression,
anxiety and sleep disturbances. Meta-analyses suggest that
pain with neuropathic characteristics has a prevalence of
7–10% in the general population (van Hecke et al., 2014)
and that large numbers of neuropathic patients fail to achieve
adequate relief from currently available treatments (Finnerup
et al., 2010; Finnerup et al., 2015). These studies highlight the
urgent need for novel classes of therapeutics and better
utilization of currently available treatments. In an attempt
to address this ongoing challenge, the ﬁrst-in-class drug
ziconotide (Prialt™) was developed as a synthetic version
of the Cav2.2 channel blocker ω-conotoxin MVIIA,
derived from Conus magus, and is licensed for chronic pain.
However, due to the narrow therapeutic window and
considerable side effects, ziconotide is only administered
intrathecally to patients who have failed to respond to other
treatments (Sanford, 2013).
As a rare example of bench-to-bedside translation,
intrathecal ω-conotoxins were demonstrated to be anti-
nociceptive in neuropathic animals over 20 years ago
(Chaplan et al., 1994). Pain has both sensory and affective
dimensions but is also a subjective experience; hence by
deﬁnition, pain in animals must be inferred. As in this study,
most animal behavioural experiments rely on evoked reﬂex
withdrawals to assess ‘pain responses’. A binary outcome
measure of this nature renders it near impossible to correlate
the intensity of a stimulus with the level of response given
that a reﬂex response determines the ﬁrst point at which a
stimulus becomes aversive. As a consequence, the validity of
stimulus-evoked reﬂexes as predictors of clinical efﬁcacy has
been questioned in light of the fact that many
pharmacological agents are efﬁcacious in preclinical models,
including calcium channel blockers, but fail to translate into
the clinic (Percie du Sert and Rice, 2014). The thorny issue of
translation is of course far more complex, and there are
numerous instances where choice of appropriate endpoints
and identifying underlying mechanisms of neuropathy has
led to successful forward and back-translation. Heterogeneity
of patient populations is likely to have led to the failure of
many clinical trials and sensory proﬁling and stratiﬁcation
of patients as an alternate approach to aetiological grouping
may lead to better indicators of successful treatment (Baron
et al., 2012; Freeman et al., 2014; Bouhassira and Attal,
2016). For example, in diabetic neuropathy, low conditioned
pain modulation (CPM) predicts efﬁcacy of duloxetine and
tapentadol (Yarnitsky et al., 2012; Niesters et al., 2014), and
in peripheral neuropathy patients, oxcarbazepine was
more efﬁcacious in those with the irritable nociceptor versus
the non-irritable phenotype [number needed to treat (NNT)
of 4 and 13 respectively] (Demant et al., 2014). As illustrations
of successful back-translation, in the spinal nerve ligation
(SNL) model of neuropathy in rats, CPM or diffuse noxious
inhibitory controls are absent and can be restored by
reboxetine and tapentadol, and carbamazepine inhibits
spinal neuronal excitability (Chapman et al., 1998; Bannister
et al., 2015). In this respect, the SNL model could represent
comparable underlying mechanisms to patients with low
CPM or the irritable nociceptor phenotype and thus provides
a basis for forward translation. Calcium channel activity
could be surmised to be favoured in the SNL model and in
patients with the irritable nociceptor phenotype, and so,
heterogeneous patient groups based on aetiology only may
not provide adequate sensitivity for revealing effects of these
drugs.
Most clinical trials continue to rely on ongoing pain
scores as a primary clinical endpoint, though more recently
in smaller trials, there has been a concerted effort to perform
quantitative sensory testing and classify patients according to
their sensory proﬁle (Bouhassira and Attal, 2016). This
approach attempts to provide a quantitative and qualitative
read-out of the patient’s pain state. In terms of a comparable
translatable measure, electrophysiological characterizations
of neuronal excitability in animals allow reproducible,
objective and quantitative measures of sensory neuronal
processing to multiple modalities and have the advantage of
examining responses to supra-threshold and brush
stimulation which are not particularly amenable to
behavioural testing. Ongoing or paroxysmal pain has been
difﬁcult to demonstrate in animal models but is a major cause
of suffering and poor quality of life in neuropathic patients.
As ongoing pain is unpleasant and aversive in its nature,
and pain relief is rewarding, a conditioned place preference
(CPP) assay in rodents was developed to explore whether
injured animals associate with contextual cues afﬁliated with
relief. This method has demonstrated efﬁcacy of clinically
used drugs such as intrathecal clonidine (King et al., 2009).
Calcium channel blockers have been successfully
developed for the treatment of absence seizures and are an
emerging drug class for the treatment of neurological
disorders and chronic pain (reviewed in detail by Zamponi,
2016). In this review, we provide an updated overview of the
effects of calcium channel blockers in chronic pain models,
with a particular focus on how electrophysiological and CPP
studies may provide insight into sensory and affective
dimensions of pain. Additionally, we consider the prospects
of voltage-gated calcium channels (VGCCs) as targets for
chronic pain and how preclinical data may guide design of
clinical trials.
Targeting trafﬁcking of VGCCs
Auxiliary calcium channel subunit α2δ-1
By far and away, the most frequently prescribed calcium
channel modulators for neuropathic pain are the
gabapentinoids, gabapentin and pregabalin. Gabapentin
and the newer derivative pregabalin were designed as
analogues of GABA. As it transpired, gabapentin was
identiﬁed as a ligand for the auxiliary voltage-gated calcium
channel subunit α2δ rather than GABA receptors (Gee et al.,
1996). Transgenic approaches strongly support that the
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interaction of gabapentinoids with α2δ-1 is required for anti-
nociceptive activity in neuropathic conditions given the lack
of efﬁcacy in the corresponding null mice (Field et al., 2006;
Patel et al., 2013). At the cellular level, it is unclear precisely
how gabapentinoids disrupt transmitter release, but a direct
block of channel activation seems highly unlikely (Hendrich
et al., 2008). Instead, gabapentin has been shown to inhibit
axonal trafﬁcking of α2δ-1, which is elevated in injured
primary afferents, and also recycling of calcium channel
complexes between intracellular compartments and the
synaptic membrane (Bauer et al., 2009; Tran-Van-Minh and
Dolphin, 2010) (Figure 1). The selective anti-nociceptive
effects in facilitated states imply injury-induced factors that
inﬂuence efﬁcacy (reviewed in detail by Patel and Dickenson,
2016). Thus, it would be expected that clinical correlates of
these mechanisms would be a determinant of the action of
these drugs and so affect their NNT.
In behavioural assays, acute, systemically administered,
gabapentin exhibits state-dependent anti-nociceptive
activity when assessed by changes in withdrawal threshold
(Field et al., 1997). Both spinal and supra-spinal
mechanisms are likely to be involved as intrathecal and
intracerebroventricular pregabalin increase withdrawal
thresholds after peripheral nerve injury (Takeuchi et al.,
2007). Likewise, when examined against spinal wide
dynamic range (WDR) neuronal responses, gabapentin
displays state-dependent inhibitory activity. Increased
descending facilitatory drive is key in shaping the
inhibitory effects of acute gabapentin treatment after nerve
injury, and remarkably, mimicking enhanced descending
facilitation in naïve rats recreates the permissive state for
gabapentin to act (Suzuki et al., 2005). Increased activity in
this pathway underlies the efﬁcacy of pregabalin in a model
of opioid-induced hyperalgesia where no injury exists
(Bannister et al., 2011).
In models where central sensitization is evident, even in
the absence of pathology or where neuropathy is not the only
component, gabapentin and pregabalin reduce spinal
neuronal ﬁring to both mechanical- and heat-evoked
responses across low and high intensities of stimulation
(Donovan-Rodriguez et al., 2005; Omori et al., 2009;
Bannister et al., 2011; Thakur et al., 2012). Patients with
osteoarthritis frequently report pain with neuropathic
characteristics (Ohtori et al., 2012), and similarly, rodent
models of osteoarthritis can be characterized by a
neuropathic component leading to cutaneous sensitization
outside the injured area which is sensitive to pregabalin
inhibition (Rahman et al., 2009; Thakur et al., 2012). In
contrast, animal models of osteoarthritis lacking neuropathic
characteristics are not sensitive to pregabalin anti-
nociception (Thakur et al., 2012). Correspondingly, there is
some evidence that patients reporting pain using
neuropathic descriptors respond positively to combination
therapy with pregabalin and advocates the beneﬁts of
stratiﬁcation of patients (Ohtori et al., 2013). A complex
interplay of inﬂammatory, neuropathic and disease-speciﬁc
Figure 1
Approaches to calcium channel modulation in chronic pain. To date, targeting trafﬁcking of VGCCs has been the favoured approach to
modulating channel activity. The gabapentinoids (GBP) bind to an argininemotif of the α2 subunit of α2δ-1 and α2δ-2 and inhibit axonal trafﬁcking
of α2δ-1 and Rab11-dependent recycling of endosomal channels to the synapse (Bauer et al., 2009; Tran-Van-Minh and Dolphin, 2010). Novel
approaches to reduce trafﬁcking include utilizing CBD3 peptides to disrupt the interaction between VGCCs and CRMP2. Channel activity can
be regulated via inhibitory GPCRs such as α2 adrenoreceptors, GABAB and μ-opioid receptors. Peptide blockers act by either altering gating by
targeting voltage sensitive domains (such as ω-agatoxin) or by directly blocking the pore (ω-conotoxins) (Bourinet and Zamponi, 2016).
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components leads to pain chronicity in a rat model of cancer-
induced bone pain, with one consequence being a
phenotypic change in the ratio of WDR-to-nociceptive
speciﬁc (NS) neurones in the superﬁcial dorsal horn. Chronic
gabapentin not only inhibits enhanced frequencies of ﬁring
in this model but normalizes the ratio of neuronal response
proﬁles (Donovan-Rodriguez et al., 2005). In comparison,
spinal nerve-ligated rats do not display similar increases in
neuronal ﬁring frequency in the dorsal horn. Instead, an
increase in population coding is proposed to mediate
hypersensitivity which subsequently converges onto
thalamic relays. In the ventral posterolateral (VPL) thalamus
of SNL rats, mechanical- and cold-evoked responses, and to
a lesser extent heat responses, of WDR and NS neurones are
increased and pregabalin normalizes neuronal coding in a
modality selective manner (mechanical and heat) at
intensities evoking elevated responses (Patel and Dickenson,
2016). Mechanically evoked responses (brush and punctate
stimuli) are inhibited to a greater extent compared with heat
stimuli, and this corresponds relatively well with patient
psychophysics (Attal et al., 1998), though the contrasting
reversal of cold hypersensitivity observed in this latter study
may relate to the chronic dosing regimen.
In healthy volunteers, gabapentin is ineffective against
temporal summation of pain, and similarly with the
analogous process in rats, electrically evoked wind-up of deep
dorsal horn neurones is unaffected (Arendt-Nielsen et al.,
2011). In contrast, in a surrogate model of central
sensitization, gabapentin inhibits temporal summation
(Arendt-Nielsen et al., 2007), and there is some evidence that
wind-up is inhibited in animal models where central
sensitization is likely to be present such as in cancer-induced
bone pain and after sciatic nerve injury, though surprisingly
not after spinal nerve injury (Donovan-Rodriguez et al.,
2005; Curros-Criado and Herrero, 2007; Bee and Dickenson,
2008; Ding et al., 2014). Wind-up is a short-term process
reﬂecting activity-dependent increases in neuronal
excitability and can lead to features shared with central
sensitization such as expansion of receptive ﬁeld size,
inducing wind-up at lower frequencies and overlapping
pharmacological dependencies (e.g. reversal by NMDA
antagonists) (Li et al., 1999). Thus, wind-up could act as a read
out of sensitization state, and pharmacological agents that
inhibit wind-up may also reverse central sensitization.
When ongoing pain scores are used as a clinical endpoint,
the NNT for gabapentin and pregabalin is approximately 7,
although this varies across different aetiologies (Finnerup
et al., 2010; Finnerup et al., 2015). Thus, when assuming
homogeneity amongst patients, most fail to achieve adequate
relief. Post hoc sensory proﬁling analysis, however, reveals
that the presence of pinprick hyperalgesia is a predictor of
efﬁcacy in human immunodeﬁciency virus (HIV)-induced
neuropathy (Simpson et al., 2010) and correlates with
surrogate models of sensitization in humans and neuronal
characterizations in rodents as gabapentin and pregabalin
reduce mechanical hypersensitivity (Werner et al., 2001;
Dirks et al., 2002; Segerdahl, 2006; Chizh et al., 2007; Patel
and Dickenson, 2016). In CPP assays, neither gabapentin
nor pregabalin has rewarding properties in the absence of
injury (Andrews et al., 2001), whereas in neuropathic and
inﬂammatory models, gabapentin has been demonstrated
to activate reward pathways (Xie et al., 2014; Griggs et al.,
2015; Park et al., 2016), though notably this occurs at 10-fold
higher doses than required to inhibit spinal neuronal
responses to evoked stimulation (Suzuki et al., 2005). The
mechanisms that underpin ongoing pain may be distinct
from those that mediate evoked pain. The neural
mechanisms by which gabapentin provides relief from
ongoing pain are poorly characterized. Despite reports of
reductions in spontaneous spinal neuronal activity by
gabapentin (Chapman et al., 1998; Suzuki and Dickenson,
2006; Dong et al., 2013; Zhang et al., 2013), pregabalin has
no effect on aberrant spontaneous ﬁring in the ventral
posterolateral thalamus in SNL rats (Patel and Dickenson,
2016). Spontaneous and evoked activity in the right central
nucleus of the amygdala is elevated following a peripheral
nerve injury, which can be normalized by pregabalin,
suggesting that gabapentinoids may modulate activity
within corticolimbic pathways associated with affective
dimensions of pain (Goncalves and Dickenson, 2012).
Collectively, these data indicate that gabapentinoids poorly
relieve ongoing pain in patients but are effective in reducing
areas of secondary sensitization and mechanical
hyperalgesia. This difference could contribute to high NNTs
if these sensory modalities were not subdivided in clinical
studies. Importantly, patients have pain scores well above
the pain threshold. As gabapentinoids attenuate the ﬁring
of spinal and thalamic sensory neurones to noxious
intensities at doses that would fully reverse behavioural
hypersensitivity to lower intensity stimuli, these may act as
a better predictor of their anti-hyperalgesic effect.
Collapsin response mediator protein 2 (CRMP2)
Even though gabapentinoids can be effective for the
management of pain, they are not without adverse effects
such as ataxia, nausea, somnolence and dizziness. Thus,
new approaches to target channel trafﬁcking have been
explored. CaV2.2 channels present in the presynaptic
terminals of primary afferent ﬁbres forms part of a large
complex of proteins and other molecules including a
regulatory protein CRMP2. This protein has been shown to
enhance membrane trafﬁcking of Cav2.2 channels, and
CRMP2 knockdown reduces calcium currents and transmitter
release, suggesting that Cav2.2 channels require the presence
of this protein for normal function (Chi et al., 2009). CBD3 is
a 15-amino acid peptide region (ARSRLAELRGVPRGL) of
CRMP2 that binds to Cav2.2 channels, and a CBD3 and TAT
(HIV-1 trans-activator of transcription) conjugated brain
penetrant peptide has been shown to block the interaction
of CRMP2 and Cav2.2 channels (Francois-Moutal et al.,
2015). Electrophysiological studies in rat spinal cord splices
demonstrated that perfusion with TAT-CBD3 reduces CGRP
release (Brittain et al., 2011). Unlike the gabapentinoids,
TAT-CBD3 does not display pathological state-dependent
activity and inhibits acute nociception and inﬂammation-
induced hypersensitivity but not nerve injury-induced
hypersensitivity (Wilson et al., 2011; Francois-Moutal et al.,
2015). At effective analgesic doses, TAT-CBD3 does not
produce motor impairment, paralysis or cognitive deﬁcits in
rats (Wilson et al., 2011). A similar peptide, R9-CBD3-A6K,
has no aversive or rewarding properties in sham rats
but activates reward pathways in a neuropathic state
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(Xie et al., 2016). Taking into account these results,
TAT-CBD3 could be a potential drug for the treatment of
chronic pain, though the poor bioavailability and short
half-life of peptide agents limits their usefulness.
Targeting α1 VGCC subunits
Activation state-independent channel blockers
CaV1 (L-type), CaV2.1 (P/Q-type), CaV2.2 (N-type), CaV2.3
(R-type) and CaV3 (T-type) channels are ubiquitously
distributed in the central and the peripheral nervous system.
In the dorsal horn, CaV2.1 and CaV2.2 channels are
predominantly localized in the presynaptic terminals of
largely non-overlapping populations of primary afferent
ﬁbres, whereas CaV1 and CaV2.3 channels are more
commonly associated with somata and dendrites
(Westenbroek et al., 1998) (Figure 2). CaV2.1 and CaV2.2
channels mediate release of neurotransmitters such as
glutamate, substance P and CGRP from primary afferent
ﬁbres causing the activation of second-order neurones
(Santicioli et al., 1992; Luebke et al., 1993; Terashima et al.,
2013). CaV1 and CaV2.3 channels on the other hand are
associated with post-synaptic excitability; the former appears
to underlie the ability of a subset of dorsal horn neurones to
mount signiﬁcant trains of post-discharge (Morisset and
Nagy, 1999), whereas the genetic ablation of the latter
demonstrates little role in basal nociception but a reduction
of inﬂammatory hypersensitivity (Saegusa et al., 2000).
ω-agatoxin IVA. In trigeminal second-order neurones,
ω-agatoxin IVA has a small inhibitory effect on cold-
evoked responses but enhances spontaneous activity in a
GABAA receptor-sensitive manner (Ebersberger et al., 2004),
consistent with a projection to both excitatory and
inhibitory interneurones in the dorsal horn (Westenbroek
et al., 1998). Spinally application of the CaV2.1 channel
blocker, ω-agatoxin IVA, has a low inhibitory effect on
spinal WDR neuronal responses to innocuous and noxious
mechanical stimulation in normal rats (Nebe et al., 1997;
Matthews and Dickenson, 2001a) and has a similar
magnitude of effect in SNL rats (Matthews and Dickenson,
2001a). In contrast, the potency of ω-agatoxin IVA is
enhanced after an acute inﬂammatory insult (Nebe et al.,
1997) and supports a role of CaV2.1 channels in the
development of sensitization but argues against a
pathophysiological role in a chronic neuropathic state.
CaV3 channel blockers. Likewise, in uninjured conditions,
the CaV3 channel blocker ethosuximide modestly inhibits
WDR responses to mechanical and heat stimulation and
exhibits similar potency after peripheral nerve injury
(Matthews and Dickenson, 2001b), again arguing against a
pathophysiological role of spinal CaV3 channels at least.
Unlike CaV2.1 and CaV2.2 channels, CaV3 channels activate
at voltages close to resting membrane potential and the
gating properties permit regulation of oscillations and burst
ﬁring. Intrathalamic delivery of Z944, an activation state-
dependent CaV3.2 blocker, reduces burst ﬁring in the VPL of
neuropathic rats, an observation that correlates with the
establishment of CPP when Z944 is dosed systemically
(LeBlanc et al., 2016). Peripherally expressed CaV3.2
channels may also be important as they modulate
excitability of a subset of mechanoreceptors (Shin et al.,
2003), and CaV3-mediated currents are enhanced in injured
dorsal root ganglion (DRG) neurones (Jagodic et al., 2008).
In SNL rats, the peripherally acting state-dependent blocker,
ABT-639, reduces spinal WDR neuronal responses to low
intensity mechanical stimulation (Jarvis et al., 2014).
ω-conotoxin GVIA. Studies have shown that, α1B (CaV2.2)
deﬁcient mice have a normal life span and normal
behaviour, however have impaired basal nociception and
development of neuropathy (Hatakeyama et al., 2001;
Saegusa et al., 2001). The role this channel plays in the
transmission of nociceptive stimuli is further supported by
electrophysiological studies demonstrating that
ω-conotoxin GVIA inhibits mechanical- and heat-evoked
responses and wind-up of spinal WDR neurones consistent
Figure 2
Expression of VGCCs in the dorsal horn. CaV2.1 (P/Q-type) and
CaV2.2 (N-type) channels are largely expressed in distinct
populations of primary afferents with the latter associated with
peptidergic transmitters (Westenbroek et al., 1998). CaV3.2 (T-type)
channels are expressed in CGRP+ and IB4+ DRG neurones and also in
cutaneous nerve endings (Rose et al., 2013). Both populations
synapse with markers of excitatory (EI) and inhibitory (II)
interneurons which subsequently converge onto second-order
sensory neurones (SN). The effects of state-independent blockers
on reducing excitatory transmission from primary afferents may be
countered by opposing effects in reducing inhibitory transmitter
release; for example, CaV2.2 channels have been shown to mediate
noradrenaline release from sympathetic neurones, though it is
unclear precisely how monoamines are released in the dorsal horn.
L-type (CaV1) and T-type (CaV3) channels inﬂuence post-synaptic
excitability; neuroplasticity in L-type expression after injury may
inﬂuence neuronal sensitization (Radwani et al., 2016), whereas
spinally expressed T-type channels, unlike peripherally expressed
channels, are not thought to have a pathophysiological role in
neuropathy. R-type (CaV2.3) channels, however, have been
implicated in neuronal hyperexcitability in SNL rats (Matthews
et al., 2007).
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with a role in mediating peptide release and consequentially
post-synaptic hyperexcitability. Dural afferents also express
CaV2.2 channels, and blockade reduces cold-evoked and
spontaneous activity of trigeminal nucleus neurones
(Ebersberger et al., 2004). The increased potency of
ω-conotoxin GVIA after SNL indicates injury-induced
neuroplastic changes in channel expression and/or
regulation in the dorsal horn (Matthews and Dickenson,
2001a). In contrast, no change in the effect size of
ω-conotoxin GVIA is observed on spinal WDR neurones
innervating the knee following knee inﬂammation
(Neugebauer et al., 1996). Intrathecal ω-conotoxin MVIIA
can induce CPP in SNL rats demonstrating an alleviation of
ongoing pain and correlates well with clinical observations
(King et al., 2009).
ω-Conotoxins are small peptides derived from the venom
of marine cone snails and block a series of ion channels.
These peptides are thought to act by physical occlusion of
the α1 ion conducing pore (Bourinet and Zamponi, 2016).
In animal models, conotoxins such as GVIA, MVIIA and
CVID have analgesic properties against inﬂammatory and
neuropathic pain; however, they have also been shown to
have a series of negative side effects in patients such as
dizziness, nausea, nystagmus, gait abnormality, urinary
retention, memory impairment and hallucinations. Some of
them such as GVIA have irreversible effects once they bind
to the pore, which complicates its usage. MVIIA, also known
as ziconotide has been the ﬁrst ω-conotoxin to enter clinical
trials and was approved in 2004 by the FDA, for the
management of chronic pain. Initial clinical trials conducted
in patients with chronic pain, cancer-related or AIDS-related
neuropathy refractory to opioid treatment reported
improvement of VAS (visual analogue scale) scores (from a
mean baseline of >70/100) by 14 to 53%, while the
proportion of responders ranged from 16 to 50% (Sanford,
2013). The dosage was often titrated to tolerable levels which
may account for some of the variability in effect size. Even
though ziconotide does not produce tolerance or addiction
like morphine does, it has adverse neurological side effects
that need to be taken into account before prescribing the drug
to a patient. In addition, its large amino acid sequence has
some limitations. For instance, manufacturing the drug is
challenging and expensive. Due to its large size, ziconotide
poorly crosses the brain–blood barrier, thus needs to be
delivered straight into the spinal cord or in the surrounding
cerebrospinal ﬂuid for the treatment of pain.
Due to the limitations of ziconotide, there is a need to
develop newer blood–brain barrier penetrable small molecule
calcium channel blockers with fewer adverse effects as well as
drugs that are orally available. Several new activation state-
dependent blockers have been developed and tested in
animal models with some progressing to clinical trials.
Activation state-dependent channel blockers
ZC88. ZC88 ((N-[1-(2,3-dimethoxyphenyl)-4-methyl-3-
pentene-1-yl]-1-(5-bromo-furfuryl)-1-piperidyl-4-amine dihy-
drochloride)) is a non-peptide, state-dependent, blocker of
CaV2.2 channels and does not affect calcium currents
mediated by CaV1, CaV2.1 or CaV2.3 channels in cultured
DRG neurones (Zhang et al., 2015). Behavioural studies in a
rat chronic constriction injury model of neuropathic pain
show a dose-dependent decrease of mechanical
hypersensitivity after oral administration of ZC88 (Meng
et al., 2008). However, ZC88 administration has no effect on
acute nociception in normal mice in the hot plate test but
enhances morphine analgesia. This synergy may arise as
opiates can inhibit CaV2.2 via Gi/o protein-coupled μ-opioid
receptors. As chronic treatment with morphine is associated
with tolerance and addiction, Meng et al., (2008) tested the
effects of ZC88 in animals that had been chronically treated
with morphine. In isolation, ZC88 does not produce CPP in
uninjured mice. However, in combination with morphine,
ZC88 reverses tolerance to chronic morphine in the hot plate
test without affecting morphine-induced CPP. These results
are promising, as ZC88 could be a potential drug against
neuropathic pain that could be administered together with
morphine or used alone.
A-1264087. A-1264087 (N2-methyl-N-{(3aR,4S,6aS)-2-[4-
(triﬂuoromethyl)phenyl]octahydrocyclopenta[c]pyrrol-4-yl}-
l-leucinamide) is a state-dependent blocker of CaV2.1, CaV2.2
and CaV3 channels. This drug has been shown to block
CaV2.2 channels in cultured rat DRG neurones as well as to
reduce spontaneous and mechanical-evoked activity of
WDR neurones in SNL animals. Systemic administration
reduces mechanically evoked neuronal responses to low-
intensity von Frey ﬁlaments as well as Aδ-ﬁbre and C-ﬁbre-
evoked responses to electrical stimulation and subsequent
wind-up, selectively in neuropathic rats (Xu et al., 2014).
Correspondingly, using withdrawal reﬂexes as an endpoint,
A-1264087 after oral administration in SNL rats and the
iodoacetate model of osteoarthritis attenuates mechanical
hypersensitivity (Xu et al., 2014; Zhu et al., 2014). Both of
these studies report a decrease in neuronal responses to
mechanical stimulation. However, neither of these studies
assessed changes in neuronal responses to other modalities
or to more noxious intensities of stimulation where C-ﬁbres
are recruited. Thus, it would be interesting to further
analyse the effects of A-1264087 on high intensities of
stimulation. Interestingly, in SNL rats, spontaneous spinal
neuronal activity is reduced by A-1264087 when dosed
spinally but not when delivered directly to the receptive
ﬁeld (Xu et al., 2014). It would be of value to investigate the
effects in operant-based assays to examine whether
A-1264087 alleviates ongoing as well as evoked pain.
TROX-1. N-triazole oxindole (TROX-1) is an orally
bioavailable, blood–brain barrier penetrating, state-
dependent blocker of the CaV2 family. In cultured cell
systems, blocking channels under depolarized conditions,
TROX-1 has similar potency across the CaV2 family, thus
acting on CaV2.1, CaV2.2 and CaV2.3 channels (Swensen
et al., 2012). Behavioural studies demonstrate that in animal
models of acute inﬂammatory pain, oral administration of
TROX-1 reverses behavioural hypersensitivity (Abbadie
et al., 2010). However, in CaV2.2 knockout mice, TROX-1 is
ineffective, suggesting that TROX-1 primarily mediates its
effects through CaV2.2 channels in inﬂammatory
conditions, despite evidence that CaV2.3 channels also
contribute to spinal neuronal hyperexcitability after injury
(Matthews et al., 2007).
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TROX-1 is also anti-nociceptive in more severe chronic
models of pain. Behavioural assessments have also shown
that TROX-1, given by oral, subcutaneous and intrathecal
routes, increases paw withdraw thresholds in SNL rats in a
dose-dependent manner with no effect in sham-operated
animals (Abbadie et al., 2010; Patel et al., 2015). In
concordance with these behavioural results, in vivo
electrophysiological recordings in SNL rats showed a
reduction of neuronal-evoked responses to low intensity
and supra-threshold mechanical stimulation with von Frey
ﬁlaments after spinal and systemic administration of
TROX-1 (Patel et al., 2015). This effect was modality
selective; brush-, heat- and cold-evoked responses were
unaffected by TROX-1 in the SNL model. Unlike
ω-conotoxin GVIA, TROX-1 had no effect on neuronal
wind-up. This is despite displaying use dependency in cell
lines in vitro using comparable stimulus parameters, which
highlights the importance of physiological assays when
assessing drug actions.
As described earlier, rodent models of osteoarthritis can
share common features with neuropathy resulting from
peripheral nerve damage, for example, concurrent time-
dependent increases in descending facilitatory drive and loss
of descending noradrenergic inhibition (Rahman et al., 2009;
Burnham and Dickenson, 2013). Hence, the effects of
TROX-1 were additionally examined in the rat intra-articular
iodoacetate model of osteoarthritis, where treatment with
TROX-1 reversed behavioural hypersensitivity and weight-
bearing behaviour (Abbadie et al., 2010). In vivo
electrophysiological studies have also assessed the efﬁcacy
of TROX-1 in the iodoacetate model of osteoarthritis. Spinal
administration of TROX-1 inhibits evoked WDR neuronal
responses to dynamic brush, heat and mechanical
stimulation in a dose-dependent manner (Rahman et al.,
2015). Systemic administration of this drug reduces supra-
threshold mechanically evoked responses to von Frey
ﬁlaments, but does not affect heat and dynamic brush
responses, perhaps because a more local administration of
the drug (spinal administration) allows for attenuation of
these modalities. In sham animals, TROX-1 does not affect
the neuronal responses after evoked stimulation. As observed
in SNL rats, TROX-1 does not reduce wind-up in arthritic rats;
the differential effects of A-1264087 and TROX-1 on wind-up
may relate to the selectivity proﬁles of the drugs. Inactivation
of the rostral ventromedial medulla with lidocaine in
osteoarthritic rats induces CPP and reveals the presence of
ongoing pain (Havelin et al., 2016); as with A-1264087 and
ZC88, it would be of interest to examine whether TROX-1
modulates affective dimensions of pain. Together, these
results suggest that the use of state-dependent blockers for
the treatment of osteoarthritic pain with neuropathic
features could be a good alternative to current treatments.
The differences between the actions of TROX-1 in different
pain conditions might be due to differences in state-
dependency of the channel such as the depolarizing effect
of ionotropic facilitatory 5-HT3 receptors on pre-synaptic
terminals, altered G-protein-mediated regulation by
adrenoceptors, GABA- and metabotropic 5-HT
receptors, or changes in the up-regulation of C-terminus
splice variants of calcium channels which might contribute
to changes in biophysical properties of the channel.
When new drugs are developed, the implications of
alternative splicing and the effects it has on channel activity
are rarely considered. Multiple variants are predicted to
exist, but in particular, mutually exclusive exons e37a and
e37b of CaV2.2 are highly enriched in DRG neurones. These
exons confer different properties to the channel, for
instance e37a-CaV2.2 exhibits larger calcium currents,
increased channel open time and slower inactivation than
e37b-CaV2.2 (Castiglioni et al., 2006). VGCCs with these
gating properties could be more amenable to block by
state-dependent blockers. However, the role of splice
variants in the pathophysiology of neuropathic pain is
complex. RNA knockdown has shown that the e37a isoform
mediates the transmission of mild mechanical stimulation
and heat stimulation and prevents the development
of mechanical hypersensitivity in neuropathic and
inﬂammatory models (Altier et al., 2007). Paradoxically,
following peripheral nerve injury, there is a decrease in the
expression of the e37a isoform (Altier et al., 2007).
Neuroplastic shifts in splice variant expression with
differences in drug sensitivity and sensitivity to G-proteins
could affect the efﬁcacy of analgesics after injury, including
morphine (Jiang et al., 2013), but also, the gabapentinoids
as the predominant α2δ-1 splice variant up-regulated after
nerve injury has reduced afﬁnity for gabapentin (Lana
et al., 2014).
Are calcium channels a good target for
chronic pain?
Due to their critical role in transmitter release, calcium
channels are regarded as an important target in preventing
sensory transmission. However, the ubiquitous nature of
expression and multitude of processes controlled by calcium
channels has complicated the use of blockers for chronic
pain (reviewed in detail by Zamponi et al., 2015). Although
spinally delivered state-independent blockers can reduce
behavioural and spinal hyperexcitability, micro-injection of
peptide blockers into brainstem regions mediating
descending control of pain reveals complex pro- and anti-
nociceptive roles of calcium channels and could confound
usage of blockers via a systemic route (Figure 3). Targeting
nociceptor speciﬁc splice variants to improve speciﬁcity
and reduce side effects seems unlikely to yield positive results
given the notorious difﬁculty in identifying selective low
MW blockers of ion channels, let alone selective blockers
for splice variants that differ only by small sequences. In
theory, state-dependent blockers would circumvent the
confounds of blocking calcium channels by targeting high-
frequency neuronal ﬁring associated with neuropathic pain.
In this aspect, compounds such as CNV2197944 (Cav2.2),
ABT-639 (Cav3.2) and Z160 (Cav2.2), which exhibit
activation state dependency, were generally well tolerated
in phase I clinical trials. Unfortunately, Z160
(NCT1655849) and ABT-639 (NCT01345045) failed to show
analgesic efﬁcacy in phase II trials, whereas results for
CNV2197944 have not been reported yet (NCT01848730
and NCT01893125).
Z160 is anti-nociceptive in a range of animal models
when examined against withdrawal reﬂexes (Lee and
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Snutch, 2013) but failed in phase II trials with ongoing pain
as the primary endpoint. It is conceivable that a failure to
consider heterogeneity in patients during trial design led
to an overall negative outcome. Drawing parallels with
anticonvulsant sodium channel blockers which are more
efﬁcacious in patients with the irritable nociceptor
phenotype, that is, where peripheral afferents are
hyperexcitable and patients have evoked hypersensitivity,
a state-dependent calcium channel blocker could also be
efﬁcacious in this subgroup (Bouhassira and Attal, 2016;
Baron et al., 2017). Likewise, ABT-639 failed to ameliorate
ongoing pain in diabetic polyneuropathy patients (Ziegler
et al., 2015). Interestingly, ABT-639 has no effect on
spontaneous ﬁring of WDR neurones in SNL rats but
inhibits mechanically evoked ﬁring (Jarvis et al., 2014).
Diabetic polyneuropathy is most commonly associated with
the ‘sensory loss’ phenotype, whereas a smaller proportion
are classiﬁed under the ‘mechanical hyperalgesia’
phenotype (Baron et al., 2017); it is possible that ABT-639
may have had higher efﬁcacy in this subgroup in this trial
(Ziegler et al., 2015). The inability of ABT-639 to cross the
blood–brain barrier could also have contributed to an
overall negative result.
Conclusion
Despite disappointing clinical trials to date, it would be
premature to consign calcium channels as a chronic pain
target to the history books. A progressive approach to clinical
trial design will be key to the success of future therapeutic
approaches. Therapeutic agents displaying pathological state
dependency would be preferable to avoid perturbing normal
sensory function and to limit side effects. Poly-pharmacy
could be an alternative approach as gabapentin and
ω-conotoxins have demonstrated synergy with morphine
(Matthews and Dickenson, 2002; Kolosov et al., 2011). It
would be of interest to examine whether state-dependent
calcium channel blockers also exhibit similar synergistic
effects. In the short term, patients receiving intrathecal
ziconotide may beneﬁt from improved analgesia and fewer
side effects with combination therapy.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY (Southan
Figure 3
Effects of calcium channel modulators in the pain neuraxis. There are conﬂicting reports as to whether CaV2.2 channels contribute to ectopic
ﬁring in injured primary afferent ﬁbres (Chaplan et al., 1994; Xiao and Bennett, 1995). However, numerous studies demonstrate that state-
dependent and -independent blockers can reduce spinal neuronal hyperexcitability when given systemically or spinally. In addition, systemic
pregabalin reduces neuronal ﬁring in the amygdala and VPL. Neuropathy can be associated with diminished descending noradrenergic
inhibitory control of pain and enhanced serotonergic facilitatory drive. Both CaV2.1 and CaV2.2 channels have complex roles in descending
modulation and exert pro- and anti-nociceptive actions when micro-injected into different regions (Knight et al., 2002; Finn et al., 2003;
Urban et al., 2005). However, state-dependent blockers targeting high-frequency neuronal ﬁring may avoid the confounding actions of
state-independent blockers (Ce, central nucleus of amygdala; LC, locus coeruleus; PAG, periaqueductal gray; RVM, rostral ventromedial
medulla; VP, ventral posterior thalamus).
BJP R Patel et al.
8 British Journal of Pharmacology (2017) •• ••–••
et al., 2016), and are permanently archived in the Concise
Guide to PHARMACOLOGY 2015/16 (Alexander et al.,
2015a,b).
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